1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Yuyu Pharma, Inc.

Yuyu Pharma, Inc.

7,440.00
KRW
-140.00
(-1.85%)
2014 Y
2015 Y
2016 Y
2017 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
61,994
62,816
69,743
71,579
62,852
83,096
90,878
98,120
115,655
138,881
137,210
133,147
140,885
144,371
Operating Margin (%)
2.83
2.18
2.31
5.22
5.68
6.41
8.89
6.39
1.04
-0.43
0.27
9.45
7.82
9.12
Depreciation Expense
1,633
1,510
1,542
1,601
1,461
2,127
3,121
3,899
4,503
5,027
5,607
5,666
5,608
5,653
Net Income, GAAP
1,877
-7,467
-253
5,886
4,541
4,020
4,722
1,284
-2,214
-5,988
-7,181
8,720
8,154
12,504
Effective Tax Rate (%)
26.53
- -
- -
5.99
10.9
7.23
15.71
34.99
- -
- -
- -
- -
3.86
5.3
Profit Margin (%)
3.03
-11.89
-0.36
8.22
7.23
4.84
5.2
1.31
-1.91
-4.31
-5.23
6.55
5.79
8.66
Working Capital
28,344
22,673
19,809
25,453
27,987
41,082
22,558
46,068
68,873
32,042
51,621
37,468
37,967
43,111
LT Debt
3,956
- -
- -
- -
1,349
18,181
3,070
14,972
28,739
1,851
14,021
402
257
5,404
Total Equity
72,276
71,489
73,731
78,291
82,834
86,872
90,545
117,036
128,685
123,374
120,356
135,063
140,544
146,181
Return on Invested Capital (%)
1.79
- -
- -
3.94
3.34
4.63
5.91
3.26
- -
- -
- -
- -
6.28
7.42
Return on Capital (%)
2.67
- -
- -
6.47
5.2
4.26
4.59
1.02
- -
- -
- -
- -
5.68
8.57
Return on Common Equity (%)
2.72
-10.73
-0.36
7.98
5.8
4.87
5.49
1.28
-1.89
-5.08
-6.42
7.51
6.53
9.86

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
27,666
25,787
22,652
LT Borrowings
- -
- -
5,000
LT Finance Leases
257
428
404
Preferred Equity and Hybrid Capital
2,592
2,592
2,592
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
96,914
94,788
91,424
Cash, Cash Equivalents & STI
32,705
29,887
27,865
Accounts Receivable, Net
18,553
20,060
17,064
Inventories
42,221
39,486
43,180
Total Current Liabilities
58,948
56,497
48,313
Payables & Accruals
- -
- -
- -
ST Debt
27,666
25,787
22,652
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7%
3.93%
4.06%
Free Cash Flow
-122.18%
-51.1%
-57.93%
Net Income, GAAP
-282.9%
-62%
-6.49%
Sales/Revenue/Turnover
7.96%
7.92%
5.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33,405
33,177
33,600
32,966
133,147
2025
32,907
35,846
37,792
34,339
140,885
2026
35,542
36,697
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wonsang Yu
Full Time Employees
248
Sector
Health technology
Industry
Pharmaceuticals: major
Address
94 Biovalley 1-ro Jecheon-si NC South Korea 27159
IPO Date
Nov 18, 1975
Website
yuyu.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Yuyu Pharma, Inc. is a South Korean pharmaceutical company founded in 1941 and headquartered in Jecheon-si, South Korea. The company develops, manufactures, markets, and distributes a broad range of pharmaceutical products including prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, antidiabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, and topical corticosteroids. It also produces non-prescription drugs including vitamins and digestive agents, as well as healthcare supplements and quasi-drugs, targeting therapeutic areas including neurology, endocrinology, otolaryngology, osteoporosis, dementia, stroke, and chronic diseases. Yuyu Pharma operates primarily in South Korea and Southeast Asia. The company is recognized for its generic soft capsule Newmacor, an Omega-3-acid ethyl ester product for hypertriglyceridemia, which has been a leading product in its domestic market. Recently, Yuyu Pharma has established a strategic research partnership with UCLA University for multiple sclerosis treatment and is progressing in drug discovery programs addressing benign prostatic hyperplasia and dry eye syndrome. The company also focuses on developing species-specific animal therapeutics, including injectable monthly treatments for pets, and pursues collaborations with U.S. startups to advance diagnosis and treatment technologies for chronic animal diseases. Yuyu Pharma has invested in new and renewable energy facilities at its manufacturing site and continues to expand its pharmaceutical innovation and global reach while maintaining a public listing on the Korea Exchange since 1975. This profile reflects operations and developments as of late 2025.